OrbiMed

InspireMD is an innovative medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard. The company intends to apply its technology to develop products used in interventional cardiology and other vascular procedures. InspireMD’s mission is to utilize its proprietary technology to make its products the industry standard for stents and to provide a superior solution to the key clinical issues of current stenting: embolic showers, restenosis, and late stent thrombosis. InspireMD intends to pursue applications of its innovative technology both for bare metal and drug eluting stents in coronary, carotid and peripheral artery procedures.

Magenta Medical Ltd., founded in 2012 and based in Kadima, Israel, specializes in developing innovative device solutions for the treatment of acute and chronic heart failure. The company's primary focus is on a temporary venous catheter-based therapy designed specifically for patients experiencing acute decompensated heart failure. By addressing critical needs within this medical field, Magenta Medical aims to improve patient outcomes through its advanced therapeutic technologies.

DarioHealth Corp. is a digital health company focused on developing and commercializing proprietary technologies that enable consumers to conduct laboratory testing using smartphones and mobile devices. Its primary product, the Dario Smart Diabetes Management Solution, integrates a mobile application with a pocket-sized blood glucose monitoring device. This real-time, cloud-based solution assists users in managing their diabetes by offering features such as monitoring of chronic conditions, coaching, digital communication, and real-time alerts for trends and patterns. DarioHealth markets its products through direct consumer sales, retail pharmacies, hospitals, distributors, and online platforms. The company, originally known as LabStyle Innovations Corp., was founded in 2011 and is headquartered in Caesarea, Israel.

MDClone Ltd. is a company that specializes in software designed to analyze medical records while ensuring patient privacy. Founded in 2016 and based in Beersheba, Israel, MDClone's platform generates synthetic medical records for fictitious patients. This innovative approach allows researchers to study disease behavior, medical practices, and various healthcare dynamics without exposing actual patient data. The platform creates fictitious individuals with unique characteristics, preserving essential relationships between them, thus maintaining the integrity of medical information while safeguarding privacy. By enabling health organizations to harness the value of their data assets, MDClone significantly enhances the ways medical information is gathered, analyzed, and utilized in research and service delivery.

Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.

GentiBio, Inc. is a biotherapeutics company focused on developing engineered regulatory T cells (EngTregs) to treat a range of conditions, including autoimmune, alloimmune, autoinflammatory, and allergic diseases. Founded in 2020 and based in Boston, Massachusetts, with additional locations in Seattle and Israel, GentiBio utilizes a proprietary platform that combines autologous and allogeneic EngTregs. This innovative approach aims to restore immune tolerance and address the limitations found in current regulatory T-cell therapies. The company was co-founded by experts in Treg biology and synthetic immunology, emphasizing its commitment to addressing the underlying causes of diseases linked to immune system dysfunction.

Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound to cure the lung disease in cystic fibrosis patients carrying a specific splicing mutation. It is also developing a targeted modulation approach to correct the splicing pattern of CFTR transcripts according to the specific mutation carried.

Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.

ChemomAb Ltd. is a clinical-stage biopharmaceutical company based in Tel Aviv, Israel, founded in 2011. The company focuses on developing proprietary monoclonal antibodies aimed at treating autoimmune, inflammatory, and fibrotic diseases, including rare conditions. Its leading therapeutic candidate, CM-101, has undergone extensive pre-clinical testing in animal models that simulate human disorders, demonstrating promising safety and efficacy along with a novel mechanism of action. Through its innovative approach, ChemomAb aims to address unmet medical needs in immune-mediated and fibrotic disorders.

Azura Ophthalmics is a clinical-stage company focused on developing innovative treatments for Meibomian Gland Dysfunction (MGD), a leading cause of dry eye disease (DED). By addressing the underlying causes of MGD, Azura aims to improve the health and quality of life for millions affected by this and other ocular surface diseases, where effective treatment options are often limited. The company is advancing a unique portfolio of compounds in conjunction with a novel drug delivery platform, enabling healthcare professionals to better manage these conditions. Based in Tel Aviv-Yafo, Israel, Azura also has operational presence in Australia and the United States, supported by a management team with a strong track record in the development and commercialization of novel ocular therapies.

NovellusDx, Ltd. is a biotechnology company based in Jerusalem, Israel, established in 2011 by Haim Gil-ad and Yoram Altschuler. The company specializes in developing targeted therapies for cancer patients by focusing on tumor-specific driver mutations. NovellusDx utilizes innovative testing methods to evaluate the effectiveness of targeted therapy drugs on emulated tumors, allowing for the quantification of therapeutic effects. The company also monitors the oncogenic activity of relevant genes and proteins in patients, assessing changes before and after drug administration. Additionally, NovellusDx develops assays to detect the misregulated translocation of mutated signaling proteins to the nucleus, measuring the impact of drug candidates on specific tumors, particularly concerning their ability to inhibit the translocation of up-regulated signaling proteins.

MobileODT builds small, smart, connected visual diagnostic tools to enable any health provider, anywhere, to conduct examinations on the level of an expert practitioner. Empowering less-trained providers increases the reach of health systems, reducing costs, and improving outcomes. The Enhanced Visual Assessment (EVA) System is our first product, an FDA cleared internet-connected mobile colposcope and is growing rapidly in market share in the US, across Africa, and India. It is used in the world’s harshest environments and receives accolades from clinicians in the world’s leading hospitals (MD Anderson, Mount Sinai, Apollo). EVA has been used for over 40,000 procedures in 29 countries. Our customers include the world’s leading hospital groups West and East, and our fastest-growing market is the US, where we are becoming the standard for visualization (+20% of hospitals in New York State who offer Sexual Assault Forensic Examinations use EVA). We are growing rapidly in new geographies and have in the pipeline additional visual-based applications, including ENT, Oral disease, and Skin.

GentiBio, Inc. is a biotherapeutics company focused on developing engineered regulatory T cells (EngTregs) to treat a range of conditions, including autoimmune, alloimmune, autoinflammatory, and allergic diseases. Founded in 2020 and based in Boston, Massachusetts, with additional locations in Seattle and Israel, GentiBio utilizes a proprietary platform that combines autologous and allogeneic EngTregs. This innovative approach aims to restore immune tolerance and address the limitations found in current regulatory T-cell therapies. The company was co-founded by experts in Treg biology and synthetic immunology, emphasizing its commitment to addressing the underlying causes of diseases linked to immune system dysfunction.

TytoCare Ltd. develops handheld devices and application that connects people with doctor for an on-demand medical exam, diagnosis, and prescription if needed, anytime, and anywhere. The company’s tools help in examining the heart, lungs, skin, ears, throat, abdomen, and body temperature, and diagnose and treat various common conditions, such as ear infections, cold and flu, fever, headaches, eye irritation, congestion, sinus pain, allergies, sore throat, coughs and upper respiratory issues, bug bites and rashes, constipation, and stomachaches. TytoCare Ltd. has a strategic partnership with Novant Health. The company was incorporated in 2011 and is based in Netanya, Israel with an additional office in New York, New York.

ChemomAb Ltd. is a clinical-stage biopharmaceutical company based in Tel Aviv, Israel, founded in 2011. The company focuses on developing proprietary monoclonal antibodies aimed at treating autoimmune, inflammatory, and fibrotic diseases, including rare conditions. Its leading therapeutic candidate, CM-101, has undergone extensive pre-clinical testing in animal models that simulate human disorders, demonstrating promising safety and efficacy along with a novel mechanism of action. Through its innovative approach, ChemomAb aims to address unmet medical needs in immune-mediated and fibrotic disorders.

ProteKt Therapeutics is a drug development company aiming to develop potent and selective oral inhibitors of the kinase PKR for the treatment of neurodegenerative and neuroinflammatory diseases. The company has raised a $4M pre-A round and graduated from the FutuRx accelerator in 2019.

MDClone Ltd. is a company that specializes in software designed to analyze medical records while ensuring patient privacy. Founded in 2016 and based in Beersheba, Israel, MDClone's platform generates synthetic medical records for fictitious patients. This innovative approach allows researchers to study disease behavior, medical practices, and various healthcare dynamics without exposing actual patient data. The platform creates fictitious individuals with unique characteristics, preserving essential relationships between them, thus maintaining the integrity of medical information while safeguarding privacy. By enabling health organizations to harness the value of their data assets, MDClone significantly enhances the ways medical information is gathered, analyzed, and utilized in research and service delivery.

Foamix Pharmaceuticals Inc. a pharmaceutical company, engages in development and commercialization of proprietary, innovative, and differentiated topical drugs for dermatological conditions. It offers Molecule Stabilizing Technology (MST) platform. The company was incorporated in 2014 and is based in Bridgewater, New Jersey. Foamix Pharmaceuticals Inc. operates as a subsidiary of Menlo Therapeutics Inc.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies that target harmful bacteria linked to various diseases. The company aims to treat conditions associated with microbiome imbalances, including skin conditions, inflammatory bowel diseases, liver disorders, and colorectal cancer. BiomX's lead product candidates include BX001, which addresses skin appearance issues, BX002 for inflammatory bowel disease, BX003 for bacteria related to progressive liver disease, and BX004 targeting chronic pulmonary infections caused by Pseudomonas aeruginosa. The company collaborates with notable institutions such as The Weizmann Institute of Science, Takeda, Keio University, JSR Corporation, and Janssen Research & Development to advance its microbiome-based therapeutic products. Founded in 2015, BiomX leverages innovative research from its scientific collaborators to develop novel therapeutics aimed at improving health outcomes.

Foamix Pharmaceuticals Inc. a pharmaceutical company, engages in development and commercialization of proprietary, innovative, and differentiated topical drugs for dermatological conditions. It offers Molecule Stabilizing Technology (MST) platform. The company was incorporated in 2014 and is based in Bridgewater, New Jersey. Foamix Pharmaceuticals Inc. operates as a subsidiary of Menlo Therapeutics Inc.

MDClone Ltd. is a company that specializes in software designed to analyze medical records while ensuring patient privacy. Founded in 2016 and based in Beersheba, Israel, MDClone's platform generates synthetic medical records for fictitious patients. This innovative approach allows researchers to study disease behavior, medical practices, and various healthcare dynamics without exposing actual patient data. The platform creates fictitious individuals with unique characteristics, preserving essential relationships between them, thus maintaining the integrity of medical information while safeguarding privacy. By enabling health organizations to harness the value of their data assets, MDClone significantly enhances the ways medical information is gathered, analyzed, and utilized in research and service delivery.

TytoCare Ltd. develops handheld devices and application that connects people with doctor for an on-demand medical exam, diagnosis, and prescription if needed, anytime, and anywhere. The company’s tools help in examining the heart, lungs, skin, ears, throat, abdomen, and body temperature, and diagnose and treat various common conditions, such as ear infections, cold and flu, fever, headaches, eye irritation, congestion, sinus pain, allergies, sore throat, coughs and upper respiratory issues, bug bites and rashes, constipation, and stomachaches. TytoCare Ltd. has a strategic partnership with Novant Health. The company was incorporated in 2011 and is based in Netanya, Israel with an additional office in New York, New York.

Atox Bio Inc. is a biotechnology company established in 2003, based in Ness Ziona, Israel, with an additional office in North Carolina. The company specializes in developing immunomodulators aimed at treating critically ill patients suffering from acute and life-threatening conditions due to severe infections and inflammation. Atox Bio focuses on novel modulators of the immune response that target interconnected pathways of both the adaptive and innate immune systems, which are crucial in addressing infectious diseases, inflammatory diseases, and ischemia/reperfusion injuries.

ChemomAb Ltd. is a clinical-stage biopharmaceutical company based in Tel Aviv, Israel, founded in 2011. The company focuses on developing proprietary monoclonal antibodies aimed at treating autoimmune, inflammatory, and fibrotic diseases, including rare conditions. Its leading therapeutic candidate, CM-101, has undergone extensive pre-clinical testing in animal models that simulate human disorders, demonstrating promising safety and efficacy along with a novel mechanism of action. Through its innovative approach, ChemomAb aims to address unmet medical needs in immune-mediated and fibrotic disorders.

RDD Pharma, Ltd. operates as a pharma company, which engages in the development and commercialization of therapeutics for anotectal diseases and gastrointestinal disorders. It develops targeted pharmacological treatments for diseases of the anorectal region, such as anal fissures, fecal incontinence, and pruritus ani. The company was founded in 2008 and is based in Tel-Aviv, Israel with an additional office in New York, New York. As of April 30, 2020, RDD Pharma, Ltd. operates as a subsidiary of Innovate Biopharmaceuticals, Inc.

Azura Ophthalmics is a clinical-stage company focused on developing innovative treatments for Meibomian Gland Dysfunction (MGD), a leading cause of dry eye disease (DED). By addressing the underlying causes of MGD, Azura aims to improve the health and quality of life for millions affected by this and other ocular surface diseases, where effective treatment options are often limited. The company is advancing a unique portfolio of compounds in conjunction with a novel drug delivery platform, enabling healthcare professionals to better manage these conditions. Based in Tel Aviv-Yafo, Israel, Azura also has operational presence in Australia and the United States, supported by a management team with a strong track record in the development and commercialization of novel ocular therapies.

MobileODT builds small, smart, connected visual diagnostic tools to enable any health provider, anywhere, to conduct examinations on the level of an expert practitioner. Empowering less-trained providers increases the reach of health systems, reducing costs, and improving outcomes. The Enhanced Visual Assessment (EVA) System is our first product, an FDA cleared internet-connected mobile colposcope and is growing rapidly in market share in the US, across Africa, and India. It is used in the world’s harshest environments and receives accolades from clinicians in the world’s leading hospitals (MD Anderson, Mount Sinai, Apollo). EVA has been used for over 40,000 procedures in 29 countries. Our customers include the world’s leading hospital groups West and East, and our fastest-growing market is the US, where we are becoming the standard for visualization (+20% of hospitals in New York State who offer Sexual Assault Forensic Examinations use EVA). We are growing rapidly in new geographies and have in the pipeline additional visual-based applications, including ENT, Oral disease, and Skin.

Mitoconix Bio Ltd develops a novel strategy to improve mitochondrial health as a disease modifying therapeutic for neurodegenerative diseases. The company was founded in 2016 and is based in Jerusalem, Israel.

Avitide, Inc. specializes in the discovery, manufacturing, and supply of molecule-specific affinity purification solutions tailored for the biopharmaceutical industry. The company focuses on developing customized affinity separation technology that streamlines bioprocess development, minimizes program risks, enhances predictability in commercial scalability, and lowers manufacturing costs. Its innovative affinity purification solutions cater to the production of various life-saving therapeutics, including enzymes, novel scaffolds, multi-specific antibodies, gene therapies, and vaccines. Incorporated in 2012 and based in Lebanon, New Hampshire, Avitide is recognized for its rapid development service timeline, positioning itself as a key player in the biopharmaceutical sector.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies that target harmful bacteria linked to various diseases. The company aims to treat conditions associated with microbiome imbalances, including skin conditions, inflammatory bowel diseases, liver disorders, and colorectal cancer. BiomX's lead product candidates include BX001, which addresses skin appearance issues, BX002 for inflammatory bowel disease, BX003 for bacteria related to progressive liver disease, and BX004 targeting chronic pulmonary infections caused by Pseudomonas aeruginosa. The company collaborates with notable institutions such as The Weizmann Institute of Science, Takeda, Keio University, JSR Corporation, and Janssen Research & Development to advance its microbiome-based therapeutic products. Founded in 2015, BiomX leverages innovative research from its scientific collaborators to develop novel therapeutics aimed at improving health outcomes.

SteadyMed Ltd. is a medical-device company pursuing innovative devices for delivering injectable therapeutic drugs for pain relief, diabetes and other chronic conditions. The company's products are pre-filled drug-infusion patches that will be sold in conjunction with a series of pharma and device companies. Specific applications of the device will be tailored in accordance with the requirements of the company's partners.

ChemomAb Ltd. is a clinical-stage biopharmaceutical company based in Tel Aviv, Israel, founded in 2011. The company focuses on developing proprietary monoclonal antibodies aimed at treating autoimmune, inflammatory, and fibrotic diseases, including rare conditions. Its leading therapeutic candidate, CM-101, has undergone extensive pre-clinical testing in animal models that simulate human disorders, demonstrating promising safety and efficacy along with a novel mechanism of action. Through its innovative approach, ChemomAb aims to address unmet medical needs in immune-mediated and fibrotic disorders.

Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals for rare gastrointestinal conditions in infants. The company’s primary clinical programs include NTRA-2112, which addresses intestinal malabsorption in preterm infants by improving enteral nutrition tolerance, enhancing growth velocity, and reducing the length of stay in neonatal intensive care units. Another key product, NTRA-9620, targets short bowel syndrome by promoting bowel adaptation after surgical resection and minimizing reliance on parenteral nutrition. Nutrinia’s innovative approach includes oral formulations of insulin to support gut rehabilitation in infants. Founded in 2003 and based in Ramat-Gan, Israel, Nutrinia is dedicated to improving health outcomes for vulnerable populations.

Ornim, Inc. develops medical monitoring tools for the measurement of blood flow and oxygen saturation in patients. The company offers CerOx, a non-invasive monitor, which provides real-time data on oximetry and blood flow measurements of specific tissue. Its products are used for applications in neurological treatments and cardiac surgery. The company was founded in 2004 and is based in Santa Clarita, California. It has a research and development subsidiary operation in Israel.

SteadyMed Ltd. is a medical-device company pursuing innovative devices for delivering injectable therapeutic drugs for pain relief, diabetes and other chronic conditions. The company's products are pre-filled drug-infusion patches that will be sold in conjunction with a series of pharma and device companies. Specific applications of the device will be tailored in accordance with the requirements of the company's partners.

MDClone Ltd. is a company that specializes in software designed to analyze medical records while ensuring patient privacy. Founded in 2016 and based in Beersheba, Israel, MDClone's platform generates synthetic medical records for fictitious patients. This innovative approach allows researchers to study disease behavior, medical practices, and various healthcare dynamics without exposing actual patient data. The platform creates fictitious individuals with unique characteristics, preserving essential relationships between them, thus maintaining the integrity of medical information while safeguarding privacy. By enabling health organizations to harness the value of their data assets, MDClone significantly enhances the ways medical information is gathered, analyzed, and utilized in research and service delivery.

NovellusDx, Ltd. is a biotechnology company based in Jerusalem, Israel, established in 2011 by Haim Gil-ad and Yoram Altschuler. The company specializes in developing targeted therapies for cancer patients by focusing on tumor-specific driver mutations. NovellusDx utilizes innovative testing methods to evaluate the effectiveness of targeted therapy drugs on emulated tumors, allowing for the quantification of therapeutic effects. The company also monitors the oncogenic activity of relevant genes and proteins in patients, assessing changes before and after drug administration. Additionally, NovellusDx develops assays to detect the misregulated translocation of mutated signaling proteins to the nucleus, measuring the impact of drug candidates on specific tumors, particularly concerning their ability to inhibit the translocation of up-regulated signaling proteins.

Nucleix develops, manufactures, and markets non-invasive molecular cancer diagnostic tests. Its sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix offers a urine test for monitoring of bladder cancer called Bladder EpiCheck and a blood test for early detection of lung cancer called Lung EpiCheck. Adam Wasserstrom, Danny Frumkin, and Elon Ganor founded it in 2008, with its headquarters in Rehovot in Israel.

Avitide, Inc. specializes in the discovery, manufacturing, and supply of molecule-specific affinity purification solutions tailored for the biopharmaceutical industry. The company focuses on developing customized affinity separation technology that streamlines bioprocess development, minimizes program risks, enhances predictability in commercial scalability, and lowers manufacturing costs. Its innovative affinity purification solutions cater to the production of various life-saving therapeutics, including enzymes, novel scaffolds, multi-specific antibodies, gene therapies, and vaccines. Incorporated in 2012 and based in Lebanon, New Hampshire, Avitide is recognized for its rapid development service timeline, positioning itself as a key player in the biopharmaceutical sector.

TytoCare Ltd. develops handheld devices and application that connects people with doctor for an on-demand medical exam, diagnosis, and prescription if needed, anytime, and anywhere. The company’s tools help in examining the heart, lungs, skin, ears, throat, abdomen, and body temperature, and diagnose and treat various common conditions, such as ear infections, cold and flu, fever, headaches, eye irritation, congestion, sinus pain, allergies, sore throat, coughs and upper respiratory issues, bug bites and rashes, constipation, and stomachaches. TytoCare Ltd. has a strategic partnership with Novant Health. The company was incorporated in 2011 and is based in Netanya, Israel with an additional office in New York, New York.

Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals for rare gastrointestinal conditions in infants. The company’s primary clinical programs include NTRA-2112, which addresses intestinal malabsorption in preterm infants by improving enteral nutrition tolerance, enhancing growth velocity, and reducing the length of stay in neonatal intensive care units. Another key product, NTRA-9620, targets short bowel syndrome by promoting bowel adaptation after surgical resection and minimizing reliance on parenteral nutrition. Nutrinia’s innovative approach includes oral formulations of insulin to support gut rehabilitation in infants. Founded in 2003 and based in Ramat-Gan, Israel, Nutrinia is dedicated to improving health outcomes for vulnerable populations.

Atox Bio Inc. is a biotechnology company established in 2003, based in Ness Ziona, Israel, with an additional office in North Carolina. The company specializes in developing immunomodulators aimed at treating critically ill patients suffering from acute and life-threatening conditions due to severe infections and inflammation. Atox Bio focuses on novel modulators of the immune response that target interconnected pathways of both the adaptive and innate immune systems, which are crucial in addressing infectious diseases, inflammatory diseases, and ischemia/reperfusion injuries.

Medigus Ltd. is a medical device company based in Omer, Israel, that specializes in developing and marketing innovative minimally invasive endo-surgical tools and direct visualization technology. Founded in 1999, the company primarily focuses on the treatment of gastroesophageal reflux disease (GERD), a common chronic condition. Medigus has created an endoscopic system known as the SRS, which integrates a miniaturized video camera, surgical stapler, and ultrasonic alignment sights into a single device. This system allows gastroenterologists and surgeons to perform a partial anterior fundoplication endoluminally, significantly transforming GERD treatment by reducing reliance on traditional open or laparoscopic surgeries. In addition to its proprietary products, Medigus designs and manufactures endoscopy systems for partner companies, offering a range of technologies including small video cameras, video processors, and various types of endoscopes for diverse endoscopic procedures. The company operates globally across the United States, Europe, Asia, and other international markets.

Keystone Heart is a developer and manufacturer of medical devices aimed at enhancing patient care in cardiovascular procedures. The company specializes in creating embolic cerebral protection devices designed to safeguard the brain from emboli, thereby minimizing the risk of brain infarcts, stroke, neurocognitive decline, and dementia during procedures such as transcatheter aortic valve replacement and atrial fibrillation ablation. By focusing on the preservation of cerebral function, Keystone Heart aims to improve procedural outcomes and quality of life for patients undergoing structural heart interventions. The company's commitment to innovative technology and clinical research positions it as a potential leader in the field of cerebral protection during cardiac surgeries.

TytoCare Ltd. develops handheld devices and application that connects people with doctor for an on-demand medical exam, diagnosis, and prescription if needed, anytime, and anywhere. The company’s tools help in examining the heart, lungs, skin, ears, throat, abdomen, and body temperature, and diagnose and treat various common conditions, such as ear infections, cold and flu, fever, headaches, eye irritation, congestion, sinus pain, allergies, sore throat, coughs and upper respiratory issues, bug bites and rashes, constipation, and stomachaches. TytoCare Ltd. has a strategic partnership with Novant Health. The company was incorporated in 2011 and is based in Netanya, Israel with an additional office in New York, New York.

Ornim, Inc. develops medical monitoring tools for the measurement of blood flow and oxygen saturation in patients. The company offers CerOx, a non-invasive monitor, which provides real-time data on oximetry and blood flow measurements of specific tissue. Its products are used for applications in neurological treatments and cardiac surgery. The company was founded in 2004 and is based in Santa Clarita, California. It has a research and development subsidiary operation in Israel.

RedHill Biopharma Ltd. is a specialty biopharmaceutical company based in Tel Aviv, Israel, established in 2009. The company focuses on developing and commercializing innovative treatments primarily for gastrointestinal and infectious diseases. RedHill markets several gastrointestinal drugs, including Movantik for opioid-induced constipation, Talicia for Helicobacter pylori infection, and Aemcolo for travelers’ diarrhea. In addition to its marketed products, the company is advancing multiple late-stage investigational programs. These include RHB-204, which targets pulmonary nontuberculous mycobacterial infections; opaganib, a selective inhibitor with ongoing studies for COVID-19, prostate cancer, and cholangiocarcinoma; and RHB-104 for Crohn's disease. Other projects involve RHB-102 for acute gastroenteritis and gastritis, RHB-107 for cancer and inflammatory gastrointestinal diseases, and RHB-106, an encapsulated bowel preparation. RedHill Biopharma emphasizes acquiring, developing, and improving existing drugs and orphan drugs through its innovative approach to drug formulation and regulatory pathways.

Treato Ltd. operates Treato, provides social health patient intelligence solutions. The company offers health information platform that aggregates patient experiences from the Internet; and organizes them into usable insights for patients, healthcare professionals, pharma companies, and other healthcare organizations. Its Treato platform collects data from healthcare social media sites and forums; analyzes the information; and provides a window into patients’ thoughts and attitudes. The company also provides Treato Pharma, a brand intelligence service for pharma marketers and agencies to provide analytics and insights into patients’ thoughts and attitudes. Its Treato Pharma also interprets the patient voice, understands patient behaviors, gains competitive insights, extracts the right messages, expends effort into the right places, and engages in real time. Treato Ltd. was founded in 2008 and is based in Yehud, Israel.

Avitide, Inc. specializes in the discovery, manufacturing, and supply of molecule-specific affinity purification solutions tailored for the biopharmaceutical industry. The company focuses on developing customized affinity separation technology that streamlines bioprocess development, minimizes program risks, enhances predictability in commercial scalability, and lowers manufacturing costs. Its innovative affinity purification solutions cater to the production of various life-saving therapeutics, including enzymes, novel scaffolds, multi-specific antibodies, gene therapies, and vaccines. Incorporated in 2012 and based in Lebanon, New Hampshire, Avitide is recognized for its rapid development service timeline, positioning itself as a key player in the biopharmaceutical sector.

BioLineRx is a clinical-stage, publicly-traded (NASDAQ/ TASE: BLRX) biopharmaceutical development company based in Jerusalem, Israel. The Company develops products suitable for the pharmaceutical market satisfying an unmet medical need or exhibiting advantages over current therapies.

cCAM Biotherapeutics Ltd., a clinical stage company, engages in the discovery and development of novel immunotherapies to treat cancer. It offers CM-24, a humanized anti CEACAM1 monoclonal antibody that inhibits the immunosuppressive effect of CEAC AM1 for the treatment of advanced or recurrent malignancies, including melanoma, non-small-cell lung, bladder, gastric, colorectal, and ovarian cancers. cCAM Biotherapeutics Ltd. was founded in 2010 and is based in Misgav, Israel. As of July 31, 2015, cCAM Biotherapeutics Ltd operates as a subsidiary of Merck & Co. Inc.

Ornim, Inc. develops medical monitoring tools for the measurement of blood flow and oxygen saturation in patients. The company offers CerOx, a non-invasive monitor, which provides real-time data on oximetry and blood flow measurements of specific tissue. Its products are used for applications in neurological treatments and cardiac surgery. The company was founded in 2004 and is based in Santa Clarita, California. It has a research and development subsidiary operation in Israel.

SMT is a Herzliya Pituach, Israel-based medical device company founded in 2004. SMT is focused on the development and commercialization of procedural tools and accessories for use during TAVI and other complex percutaneous structural heart procedures.

Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.

Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.

Founded in March 2015, EUSA Pharma is a newly-established, profitable specialty pharmaceutical company with global reach from its headquarters in the UK and its commercial operations across Europe and the USA. Currently, EUSA Pharma has a portfolio of five approved as well as several named-patient specialty hospital products, including: Caphosol®, Xenazine®, Collatamp®, Custodiol® and Fomepizole® EUSA submitted the MAA for FOTIVDA (tivozanib HCL) as first line therapy for RCC in Q1 of 2016. EUSA Pharma has ambitious plans to expand its portfolio through acquisition and in-licensing and is led by an experienced management team with a strong record of building successful specialty pharmaceutical companies. The EUSA Pharma business is supported by significant funding raised from leading life science investor Essex Woodlands. In addition to direct commercial operations across the EU and US, EUSA Pharma also has a wide distribution network of commercial partners in Europe, the Middle East, Asia and Latin America and makes products available in approximately 40 countries across the world through this broad international platform.

Founded in March 2015, EUSA Pharma is a newly-established, profitable specialty pharmaceutical company with global reach from its headquarters in the UK and its commercial operations across Europe and the USA. Currently, EUSA Pharma has a portfolio of five approved as well as several named-patient specialty hospital products, including: Caphosol®, Xenazine®, Collatamp®, Custodiol® and Fomepizole® EUSA submitted the MAA for FOTIVDA (tivozanib HCL) as first line therapy for RCC in Q1 of 2016. EUSA Pharma has ambitious plans to expand its portfolio through acquisition and in-licensing and is led by an experienced management team with a strong record of building successful specialty pharmaceutical companies. The EUSA Pharma business is supported by significant funding raised from leading life science investor Essex Woodlands. In addition to direct commercial operations across the EU and US, EUSA Pharma also has a wide distribution network of commercial partners in Europe, the Middle East, Asia and Latin America and makes products available in approximately 40 countries across the world through this broad international platform.

Insulet Corporation is a medical device company that develops, manufactures, and sells insulin delivery systems for individuals with insulin-dependent diabetes. The company's primary product, the Omnipod System, consists of a disposable, tubeless insulin infusion device that adheres to the body for up to three days, along with a wireless personal diabetes manager for monitoring and control. Insulet markets its products through independent distributors and pharmacy channels, as well as directly to patients in the United States, Canada, Europe, and the Middle East. Founded in 2000, Insulet is headquartered in Acton, Massachusetts, and aims to enhance the quality of life for people managing diabetes through innovative technology.

Founded in March 2015, EUSA Pharma is a newly-established, profitable specialty pharmaceutical company with global reach from its headquarters in the UK and its commercial operations across Europe and the USA. Currently, EUSA Pharma has a portfolio of five approved as well as several named-patient specialty hospital products, including: Caphosol®, Xenazine®, Collatamp®, Custodiol® and Fomepizole® EUSA submitted the MAA for FOTIVDA (tivozanib HCL) as first line therapy for RCC in Q1 of 2016. EUSA Pharma has ambitious plans to expand its portfolio through acquisition and in-licensing and is led by an experienced management team with a strong record of building successful specialty pharmaceutical companies. The EUSA Pharma business is supported by significant funding raised from leading life science investor Essex Woodlands. In addition to direct commercial operations across the EU and US, EUSA Pharma also has a wide distribution network of commercial partners in Europe, the Middle East, Asia and Latin America and makes products available in approximately 40 countries across the world through this broad international platform.